1. Treatment of duodenal and gastric ulcers that have been clearly
diagnosed.
2. Patients with recurrence of duodenal ulcer after short-term treatment.
3. Persistent gastroesophageal reflux disease, patients who are ineffective
in anti-reflux measures and single drug therapy and antacid.
4. Prevention of flyback ulcer and bleeding in critical patients.
5. Gastrinoma (Zoellinger-Ellison syndrome).